Glucose-dependent Insulinotropic Polypeptide (GIP) and Lipid Metabolism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00999271
Recruitment Status : Completed
First Posted : October 21, 2009
Last Update Posted : October 21, 2009
Information provided by:
Hvidovre University Hospital

Brief Summary:
The aim of this proposal is to examine whether endogenous GIP and exogenous GIP alone and in combination with insulin affect gastric emptying (GE), appetite, energy intake, energy expenditure (EE) and plasma levels of triglycerides (TAG), free fatty acids FFA) and glycerol in man.

Condition or disease Intervention/treatment
Healthy Subjects Other: Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)

Study Type : Observational
Enrollment : 30 participants
Observational Model: Case Control
Official Title: On the Role of Glucose-dependent Insulinotropic Polypeptide, GIP, in Postprandial Metabolism in Humans
Study Start Date : August 2008
Actual Primary Completion Date : September 2009
Actual Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Dextrose

Group/Cohort Intervention/treatment
Healthy subjects
30 healthy subjects without family history of diabetes or gastrointestinal disease, a normal oral glucose tolerance test (OGTT) and no intake of medicine
Other: Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)

two different dosages:

  • 0.8 pmol/kg/min
  • 1.5 pmol/kg/min for 300 minutes

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Healthy volunteers

Inclusion Criteria:

  • Informed oral and written consent
  • Caucasians over the age of 18 years
  • Normal 75 g oral glucose tolerance test (OGTT)
  • Normal blood haemoglobin concentration
  • Normal plasma lipid profile

Exclusion Criteria:

  • First-degree relatives with diabetes and familial hypertriglyceridemia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00999271

Hvidovre Hospital
Hvidovre, Denmark, 2650
Sponsors and Collaborators
Hvidovre University Hospital

Responsible Party: University of Copenhagen Identifier: NCT00999271     History of Changes
Other Study ID Numbers: HD-2009-0025
First Posted: October 21, 2009    Key Record Dates
Last Update Posted: October 21, 2009
Last Verified: October 2009

Keywords provided by Hvidovre University Hospital:
Glucose-dependent insulinotropic polypeptide
gastric emptying
energy intake
lipid metabolism

Additional relevant MeSH terms:
Gastric Inhibitory Polypeptide
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Gastrointestinal Agents